Patent ID: 7070803

Claim:
A controlled release pharmaceutical composition for oral use comprising midodrine (ST 1085) or a pharmaceutically acceptable salt thereof and/or its active metabolite desglymidodrine (ST 1059) or a pharmaceutically acceptable salt thereof, wherein the in vitro release rate of midodrine and/or desglymidodrine has the following course of events i) a relatively fast first initial release followed by ii) a steady release or a slower release than in step i) above, which is followed by iii) a second rise in release rate that takes place 5-10 hours after start of an in vitro dissolution test and, finally, iv) a decline in release rate wherein the composition upon administration provides a relatively fast peak plasma concentration of desglymidodrine, and a therapeutically effective plasma concentration of desglymidodrine is maintained for at least about 9 hours.